Morgan Stanley’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

Morgan Stanley’s Portfolio PEAR Stock Details PEAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-37,296	Closed	-$9.51K	–	7818
2023 Q1	$9.51K	Sell	37,296 -16,264	-30%	-$14.7K	﹤0.01%	6902
2022 Q4	$63.2K	Buy	53,560 +29,326	+121%	+$61.7K	﹤0.01%	6187
2022 Q3	$49K	Buy	24,234 +22,013	+991%	+$37.4K	﹤0.01%	6419
2022 Q2	$3K	Sell	2,221 -3,420	-61%	-$13.4K	﹤0.01%	7551
2022 Q1	$29K	Buy	5,641 +3,219	+133%	+$14.6K	﹤0.01%	6984
2021 Q4	$15K	Buy	2,422 +2,102	+657%	+$18.8K	﹤0.01%	7333
2021 Q3	$3K	Buy	+320	New	+$3.16K	﹤0.01%	7622

Morgan Stanley's PEAR Position: Q2 2023 in Review

Morgan Stanley sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q2 2023, closing a stake of 37,296 shares — an estimated $9.51K sold.

Morgan Stanley first reported a position in PEAR in Q3 2021 and held it in 7 quarters. The position peaked at $63.2K in Q4 2022. 1 fund tracked by Wall St. Rank holds PEAR as of Q2 2023.

Morgan Stanley reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
Morgan Stanley sold 37,296 Pear Therapeutics, Inc. Class A Common Stock shares in Q2 2023, an estimated $9.51K.
Morgan Stanley first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q3 2021 and held it in 7 quarters.
Morgan Stanley's Pear Therapeutics, Inc. Class A Common Stock position peaked at $63.2K in Q4 2022.
1 fund tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q2 2023.

Based on Morgan Stanley's 13F filing for Q2 2023, filed 14 Aug 2023.